Fundraising Fox

Altay Therapeutics

YC W20

San Francisco, US · Founded 2019 · 6 employees · 3 known investors

altaytherapeutics.com

Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.

BiotechDigital HealthHealthtechMedical DevicesAI-powered Drug DiscoveryTherapeuticsDrug discoveryin /69914567/admin/feed/posts/@ycombinatorycombinator.com ↗

Founders & leadership· Y Combinator alumni (W20)

AOAli Ozes
Ali OzesinFounder
OOOsman Ozes
Osman OzesinFounder

Investors · 3

Competitors · 7

by search overlap

Companies competing with Altay Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase I2023$275K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$399.9K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$299.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$299.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news